Cutting-edge science requires reliable, validated antibodies against your specific target. Sometimes, these aren’t available off the shelf. At Fortis Life Sciences®, we offer recombinant monoclonal antibody development services supported by a team with over 50 years of antibody development and manufacturing experience.
We deliver a concierge service from project design through to delivery of your custom antibody. Beginning with detailed discussions to understand your project goals, our technical team works with you to craft an antibody development plan that meets your needs.
Pricing and milestones are established following detailed discussions regarding the scope of work, including:
We purify native antigens and produce both recombinant proteins and synthetic peptides in-house. That means we have complete control over their design and QC. And because we make our recombinant protein antigens, we can target proteins and protein isoforms that may otherwise not be commercially available.
Our scientists excel at making custom antibodies to:
All projects utilize target-specific B cell selection, which yields robust numbers of recombinant rabbit monoclonal antibody candidates for screening. Our robust monoclonal antibody generation platform delivers diverse clone sets, enabling you to discover and validate fit-for-purpose monoclonal antibodies.
Design goals may include:
Our milestone design puts you in control of your custom antibody development project. We generate numerous candidates for you to test in your own assays and you tell us which clones work the way you need them to. This strategy reduces the risk of failures and expensive repeats, stacking the deck as heavily as possible in your favor.
Deliverables may include:
Cell surface, secreted and intracellular targets
Anti-idiotype antibodies
Post-translational modifications (Phospho-specific antibodies)
Small molecules
Binding pair selection by competition binning
Monoclonal antibody reformatting
"We’ve been consistently pleased by Fortis’s initial candidate success rate. We’re now engaged in multiple projects with Fortis, with several anti-PTM clones about to be launched as formal genomic mapping reagents."
Michael-Christopher Keogh, PhD
Chief Scientific Officer
EpiCypher Inc.
"Some companies only splenectomize and proceed with one rabbit, whereas Fortis immunizes multiple rabbits, and these are all screened for antibodies to provide a distribution of the best potential candidates. In this way, we receive multiple options for performing our own screens."
Lori Kobayashi
Project Manager
Valted Seq
"The whole process has been very easy, because Fortis cloned each B cell, enabling it to produce more antibodies and generate high yields."
Bijan Etemad-Gilbertson, PhD
Head of Antibody Technology
NextPoint Therapeutics